# Clinical Cases: Cell Cycle and Mitosis

## Case 1: Retinoblastoma (RB1 Tumor Suppressor Loss)

### Clinical Image
![Retinoblastoma Leukocoria](case_01_image.jpg)
*Source: [Wikipedia - Retinoblastoma](https://en.wikipedia.org/wiki/Retinoblastoma) - CC BY-SA 3.0*

### Case Presentation
The parents of an 18-month-old girl notice a white glow in their daughter's left pupil visible in flash photographs, which they initially attributed to the camera angle. They also observe that she seems to have a slight inward turn of the same eye. Ophthalmologic examination reveals leukocoria (white pupillary reflex instead of normal red reflex) and esotropia. Dilated fundoscopic examination shows a large creamy-white mass in the posterior chamber, and MRI confirms an intraocular tumor without optic nerve involvement. She is diagnosed with retinoblastoma. Given the young age and unilateral presentation, genetic testing is performed and reveals a germline mutation in RB1, indicating hereditary retinoblastoma despite the unilateral presentation. The geneticist explains Knudson's two-hit hypothesis: in hereditary retinoblastoma, the child inherits one mutated RB1 allele, requiring only one somatic mutation to lose the remaining functional copy. In sporadic cases, both hits must occur somatically in the same cell, making bilateral disease rare. The Rb protein normally prevents cell cycle progression by binding and inhibiting E2F transcription factors; when both RB1 alleles are lost, E2F is constitutively active, driving uncontrolled proliferation. She undergoes chemotherapy and focal laser therapy, preserving her eye. Lifelong surveillance for secondary tumors (particularly osteosarcoma) is required given her germline mutation.

### Key Learning Points
- The Rb protein is the master regulator of the G1/S checkpoint; it binds and inhibits E2F transcription factors until phosphorylation by cyclin D-CDK4/6 releases E2F to activate S phase genes
- Retinoblastoma demonstrates Knudson's two-hit hypothesis: both alleles of a tumor suppressor must be inactivated for tumor development; hereditary cases inherit one hit and need only one somatic hit
- The Rb pathway (Rb, cyclin D, CDK4/6, p16) is functionally disrupted in the majority of human cancers through various mechanisms, highlighting its central role in proliferation control

---

## Case 2: Li-Fraumeni Syndrome (TP53 Germline Mutation)

### Clinical Image
![Li-Fraumeni Syndrome Tumors](case_02_image.jpg)
*Source: [Wikipedia - Li-Fraumeni syndrome](https://en.wikipedia.org/wiki/Li%E2%80%93Fraumeni_syndrome) - CC BY-SA 3.0*

### Case Presentation
A 28-year-old woman is diagnosed with breast cancer. Her family history is striking: her father died of a brain tumor at age 35, her brother had osteosarcoma at age 15, and her paternal aunt had adrenocortical carcinoma in childhood. Given this constellation of early-onset, diverse cancers, Li-Fraumeni syndrome is suspected. Genetic testing confirms a germline pathogenic variant in TP53. The genetic counselor explains that p53 is the "guardian of the genome," responding to DNA damage by activating cell cycle arrest (through p21 induction, which inhibits CDKs) to allow repair, or apoptosis if damage is severe. Without functional p53, cells with DNA damage continue dividing and accumulate mutations. Li-Fraumeni patients have extremely high cancer risk (nearly 100% lifetime), with characteristic tumor spectrum including soft tissue sarcomas, osteosarcoma, breast cancer, brain tumors, adrenocortical carcinoma, and leukemia. She undergoes breast cancer treatment and is enrolled in intensive surveillance including annual whole-body MRI and brain MRI. Radiation therapy is minimized when possible due to increased secondary cancer risk. Her siblings and eventually her children are offered genetic testing.

### Key Learning Points
- p53 is a transcription factor that responds to cellular stress (especially DNA damage) by activating genes for cell cycle arrest (p21), DNA repair (GADD45), or apoptosis (BAX, PUMA, NOXA)
- As the most frequently mutated gene in human cancer (>50% of tumors), p53 loss allows cells with damaged DNA to proliferate, accumulating the mutations that drive cancer progression
- Li-Fraumeni syndrome demonstrates that germline p53 mutations cause remarkably broad cancer susceptibility because p53 functions in response to all types of DNA damage in all cell types

---

## Case 3: Chronic Myelogenous Leukemia (CDK4/6 Inhibitor Therapy Concept)

### Clinical Image
![CML Philadelphia Chromosome](case_03_image.jpg)
*Source: [Wikipedia - Philadelphia chromosome](https://en.wikipedia.org/wiki/Philadelphia_chromosome) - CC BY-SA 3.0*

### Case Presentation
A 58-year-old woman with metastatic hormone receptor-positive (HR+), HER2-negative breast cancer is started on palbociclib (a CDK4/6 inhibitor) in combination with letrozole (an aromatase inhibitor). Her oncologist explains the mechanism: estrogen receptor signaling drives cyclin D expression in HR+ breast cancer, which activates CDK4/6 to phosphorylate Rb, releasing E2F and promoting proliferation. Palbociclib inhibits CDK4/6, blocking Rb phosphorylation and causing G1 arrest. Combining CDK4/6 inhibition with estrogen deprivation (aromatase inhibitor) provides synergistic cell cycle blockade. She is counseled that the main side effect is neutropenia (low neutrophil counts), requiring regular blood count monitoring. The physician notes that CDK4/6 inhibitors only work when Rb is intact; tumors that have lost Rb cannot respond because the downstream pathway is already derepressed. She asks why this drug helps breast cancer but not other cancers. The physician explains that HR+ breast cancer is particularly dependent on cyclin D-CDK4/6 pathway for proliferation, making it an ideal target. Her disease shows excellent response, with progression-free survival extended significantly compared to hormonal therapy alone.

### Key Learning Points
- CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) block the kinases that phosphorylate Rb, preventing E2F release and causing G1 arrest; they require functional Rb to be effective
- These drugs are approved for HR+ breast cancer because this tumor type is particularly dependent on cyclin D-CDK4/6-Rb pathway driven by estrogen receptor signaling
- Understanding cell cycle regulation has enabled development of targeted therapies; the cell cycle checkpoints and their regulators are important therapeutic targets in oncology